Gout Resource Center

Gout is a very common form of inflammatory arthritis, affecting ~9.2 million adults (3.9%) in the U.S. Although the etiology of gout is well understood and effective, inexpensive medications exist to treat gout, gaps in quality of care persist. Below, explore selected content from The Rheumatologist’s collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of gout. New features are added often, so check back frequently.

With more than 40 research abstracts on gout accepted for presentation at ACR Convergence 2021, filtering the noise to get to the key thoughts may be challenging. Lisa Stamp, MBChB, PhD, can help. A rheumatologist, professor of medicine and the associate dean of research at the University of Otago in Christchurch, New Zealand, she has extensively researched the pathophysiology and management of gout. She brings us the highlights in “Gout Research at a Glance: ‘My picks for the top research in gout presented at ACR Convergence 2021.’“

FEATURED ARTICLE: Refractory Gout Is a Myth: Tips from an Expert

Reducing Immunogenicity of Pegloticase ... Click here to view abstract video

Reducing Immunogenicity of Pegloticase ... Click here to view visual abstract summary

Research Roundup: Abstract Data Presented at ACR Convergence 2021

The research presented at ACR Convergence 2021 had a broad scope. Below are details on three studies that addressed cardiovascular safety in treat-to-target strategies, phase 2 study results on the efficacy of tigulixostat and the impact of patient preference on treatment adherence. Refer to the ACR meeting abstracts for full details on all of the… [Read More]

Diet & Gout Research Presented at ACR Convergence 2021

According to research from Yokose et al. presented at ACR Convergence 2021, regardless of genetic predisposition, diet influences a person’s risk of developing gout. Several recent analyses of the Global Burden of Disease (GBD) Study report a disproportionate worsening of gout burden among women, suggesting intensive dietary measures for gout prevention are indicated, especially in… [Read More]

Tigulixostat Appears Promising for the Treatment of Gout

In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.... [Read More]

Gout, Imaging & Cardiovascular Disease: 2 Experts Discuss Challenging Patients & Advanced Imaging

Experts compare using ultrasound and dual-energy computed tomography (DECT) scan when diagnosing likely gout patients, and discuss the latest insights into the intersection between gout and cardiovascular disease.... [Read More]

Updates on ACR Gout Guideline, FDA’s Febuxostat Warning & Pegloticase Therapy

A presentation at ACR Convergence 2021 discussed the 2020 ACR Guideline for the Management of Gout, the latest information on the risk of cardiovascular death associated with febuxostat and the use of pegloticase for patients with gout.... [Read More]

Gout Research at a Glance: ‘My picks for the top research in gout presented at ACR Convergence 2021’

Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2021.... [Read More]

Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.... [Read More]

Refractory Gout Is a Myth: Tips from an Expert

At this EULAR 2022 session, one expert explains why he believes refractory gout is caused by mismanagement and discusses ways around treatment obstacles.... [Read More]

Imaging Modalities in Gout: How to Use them in Clinical Practice

This EULAR 2022 session discussed the increasing role of imaging in the diagnosis of gout.... [Read More]

Treating to Target in Gout: The Trouble with Serum Urate

New analyses of treat to target in gout may lead to revisions in some guidelines. ... [Read More]

Gout Experts Share Insights Into a Variety of Challenging Gout Scenarios

Although the diagnosis and treatment of gout are sometimes straightforward, practitioners encounter challenges in patients with atypical presentations, as well as those with medically complex situations or refractory disease. Here, gout experts share insights into some of these scenarios. Flare in Hospitalized Patients When not contraindicated, the 2020 ACR Guideline for the Management of Gout… [Read More]

Case Report: Lipoma Arborescens of the Knee

Lipoma arborescens is a rare, benign intra-articular lesion characterized by diffuse replacement of synovial tissue by mature adipocytes, causing a villous lipomatous proliferation of the synovial membrane.1 Typically, this is a monoarticular condition, with the knee being the most commonly affected although it has been rarely reported to occur in an oligo-/polyarticular fashion and in… [Read More]

A Quick Reference Guide to Patient Education Materials on Gout

The following websites offer an abundance of options to help your patients understand their disease and learn to live with it. Several sites offer information in various languages, and for your patients who prefer audio-visual to print, one site has several educational videos. The ACR—Diseases and Conditions: Gout (Web page or PDF available in English… [Read More]

Gout Management Recommendations from the ACR’s 2020 Guideline

The 2020 ACR Guideline for the Management of Gout is intended to provide guidance for the management of patients with gout, and includes recommendations on the indications for and optimal use of urate-lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations.1 The guideline includes 42 recommendations, of which 16 are strong…. [Read More]

Clinical Insights into Gout Management: Q&A with Dr. Tuhina Neogi

Gout affects more than 9.2 million adults in the U.S. and is the most common form of inflammatory arthritis. This condition and its complications are painful and potentially disabling with varying risk factors. It is characterized by symptoms that are usually sudden, with intense episodes of painful swelling in one or more joints, most often… [Read More]

Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout

A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study… [Read More]

Pegloticase Proves Promising for Gout in Patients who Have Undergone Kidney Transplant

Patients who have undergone a kidney transplant and have high levels of serum uric acid symptomatic gout may benefit from treatment with pegloticase, according to a recent study.... [Read More]